Format

Send to

Choose Destination
Blood. 2014 Aug 14;124(7):1089-98. doi: 10.1182/blood-2014-01-552067. Epub 2014 Apr 28.

Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

Author information

1
Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
2
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;
3
Broad Institute, Cambridge, MA;
4
Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;
5
F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA; Department of Neurology, Harvard Medical School, Boston, MA;
6
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
7
Broad Institute, Cambridge, MA; Division of Allergy, Immunology and Rheumatology, Department of Medicine, Massachusetts General Hospital, Boston MA; and.
8
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
9
Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Abstract

One major goal of cancer genome sequencing is to identify key genes and pathways that drive tumor pathogenesis. Although many studies have identified candidate driver genes based on recurrence of mutations in individual genes, subsets of genes with nonrecurrent mutations may also be defined as putative drivers if they affect a single biological pathway. In this fashion, we previously identified Wnt signaling as significantly mutated through large-scale massively parallel DNA sequencing of chronic lymphocytic leukemia (CLL). Here, we use a novel method of biomolecule delivery, vertical silicon nanowires, to efficiently introduce small interfering RNAs into CLL cells, and interrogate the effects of 8 of 15 mutated Wnt pathway members identified across 91 CLLs. In HEK293T cells, mutations in 2 genes did not generate functional changes, 3 led to dysregulated pathway activation, and 3 led to further activation or loss of repression of pathway activation. Silencing 4 of 8 mutated genes in CLL samples harboring the mutated alleles resulted in reduced viability compared with leukemia samples with wild-type alleles. We demonstrate that somatic mutations in CLL can generate dependence on this pathway for survival. These findings support the notion that nonrecurrent mutations at different nodes of the Wnt pathway can contribute to leukemogenesis.

PMID:
24778153
PMCID:
PMC4133483
DOI:
10.1182/blood-2014-01-552067
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center